Item 2.01
Completion of Acquisition or Disposition of Assets
On December 10, 2018, NeoGenomics Laboratories, Inc. ( NeoGenomics Labs) completed the previously announced acquisition of Genesis Acquisition Holdings Corp. (Genesis), pursuant to an Agreement and Plan of Merger dated October 23, 2018 (the Merger Agreement), by and among NeoGenomics Labs, Genoptix Merger Sub, Inc. (Merger Sub), Genesis and Ampersand 2014 Limited Partnership, solely in its capacity as stockholders representative. At the closing, Merger Sub merged with and into Genesis (the Merger) with Genesis surviving the Merger as the surviving corporation and as a wholly owned subsidiary of NeoGenomics Labs. The total aggregate consideration for the transaction was $125 million in cash, as adjusted by working capital and other adjustments, and 1,000,000 shares of NeoGenomics common stock (the NEO Common Shares).
The foregoing description of the Merger Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, which was filed as Exhibit 2.1 to the Current Report of the Company on Form 8-K, filed with the Securities and Exchange Commission on October 26, 2018. All summaries and descriptions of the Merger Agreement set forth above are qualified in their entirety by the Merger Agreement.
Item 3.02Unregistered Sales of Equity Securities.
